Cancer Therapy

Photodynamic Therapy

Tumor Targeted Photosensitizers

Long Wavelength Photosensitizers

Imaging & Therapy

PET / Fluorescence





Related Publications


Photolitec Technology

Photolitec is developing new photosensitizing compounds used to identify cancer and treat the disease. Photolitec’s new compounds have the ability to image the tumors through fluorescence and/or nuclear (PET) imaging and offer what is referred to as “the see and treat approach.” Drug compounds collect in cancerous cells and work as markers for nuclear imaging, optical imaging or MRI prior to PDT treatment or surgery, or to monitor cancer treatment results. The compounds help to identify the tumor and treat it.

Photolitec is focused on moving these highly innovative cancer imaging technologies with an option of PDT, Surgery, chemotherapy and radiation therapy (a “See and Treat” approach) to human clinical trials.

Significance of Photolitec Technology

The major challenge of cancer therapy is the preferential destruction of malignant cells with sparing of the normal tissue. Critical for successful eradication of malignant disease are early detection and selective ablation of the malignancy. hotodynamic therapy (PDT) is a clinically effective and still evolving locally selective therapy of cancers. The utility of photodynamic therapy (PDT) has been demonstrated with various photosensitizers (PS) for multiple types of disease (Chem. Soc. Review, 2011, 40, 340-362 and references therein). PDT employs tumor localizing PS that produce a cytotoxic agent (singlet oxygen) upon absorption of light which is responsible for the destruction. On the tumor tissue level, PDT directly kills tumor cells by destructing the tumor supporting vasculature and possibly activating the innate and adaptive antitumor immune system which interacts to destroy the malignant tissue. The success of PDT relies on development of tumor-avid molecules that are preferentially retained in tumor cells. The Photolitec technology comprises highly tumor-avid multifunctional agents (including biocompatible nanoplatforms), which show great potential in tumor imaging [fluorescence, positron emission tomography (PET)] and PDT. Photolitec also has an innovative patented technology on an improved PET Imaging agent which circumvents current limitations of FDA approved PET agents.

The agents currently at advanced stages of development are summarized below. Click on the graphic to link to additional information.

(a) Long wavelength photosensitizers (near 800 nm) for NIR fluorescence imaging and therapy (link).

(b) Photosensitizers for PET/fluorescence imaging with an option of PDT (link).

(c) Photosensitizers for PET Imaging with an option of therapy.

(d) Optical imaging with an option of therapy.

(e) Metalleted Dual-Functional Agents for Imaging and Therapy.

(f) Multifunctional nanoplatform for PET/fluorescence imaging and photodynamic therapy (link).